Anti-angiogenic treatment of ovarian, breast, and prostate cancer with a combination of antagonists
AssigneeCalifornia Northstate College of Pharmacy, LLC
InventorXIAODONG FENG
Life of this patent
Estimating the term…
Abstract
The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).
Claims23
A method of inhibiting the growth of a solid ovarian, breast, or prostate tumor in a subject in need thereof, comprising administering in combination to the subject (i) an amount of VLO4 ranging from 0.01 μg/ml-10 μg/ml that would be less than a therapeutically effective amount of the VLO4 administered alone, and (ii) an amount of VP12 (ECL12) ranging from 0.01 μg/ml-10 μg/ml that would be less than a therapeutically effective amount of the VP12 (ECL12) administered alone;
- and, inhibiting growth of the solid ovarian, breast, or prostate tumor in the subject.
A method of inhibiting ovarian, breast, or prostate tumor invasion in a subject in need thereof, comprising administering in combination to the subject (i) an amount of VLO4 ranging from 0.01 μg/ml-10 μg/ml that would be less than a therapeutically effective amount of the VLO4 administered alone, and (ii) an amount of VP12 (ECL12) ranging from 0.01 μg/ml-10 μg/ml that would be less than a therapeutically effective amount of the VP12 (ECL12) administered alone;
- and, inhibiting ovarian, breast, or prostate tumor invasion in the subject.
A method of disrupting angiogenesis in a subject having an ovarian, breast, or prostate tumor, comprising administering an effective amount of VLO4 to the subject.
A method of disrupting angiogenesis in a subject having an ovarian, breast, or prostate tumor, comprising administering in combination to the subject (i) an effective amount of VLO4 ranging from 0.01 μg/ml-10 μg/ml that would be less than a therapeutically effective amount of the VLO4 administered alone, and (ii) an amount of VP12 (ECL12) ranging from 0.01 μg/ml-10 μg/ml;
- and, disrupting angiogenesis in the subject having the ovarian, breast, or prostate tumor.
Dependencies are inferred from the claim text.